Pivotal Research raised its price target on USANA Health Sciences Inc. (NYSE: USNA) to $135.00 (from $100.00) while maintaining a Hold rating following 'blow-out' results and higher guidance.

Analyst Timothy Ramey noted sales were positive in every geography – even the perennially-flat Americas & Europe region posted a 3.7% sales gain. Greater China sales rose 22.8% on a 7.8% increase in customer counts. North Asia powered 36.1% higher Y/Y on 20.7% greater active customers.

The firm raised 2018 estimates to $5.00, up from $4.55; 2019 goes to $6,25, up from $5.20.